Product Information

CARBIDOPA-LEVO ER 25-100 TAB is a generic product labeled by ScieGen Pharmaceuticals Inc., priced at $0.1125 per EA under NDC 50228046010. Its NADAC has been published 198 times since Feb 8, 2023.

FDA first approved this application on Oct 5, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CARBIDOPA-LEVO ER 25-100 TAB

Carbidopa and Levodopa
$0.1125per EA

Strength

25; 100 mg/1; mg/1

NDC

50228046010

Classification

Generic

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

CARBIDOPA; LEVODOPA

Approval Type

Generic (ANDA)

FDA Application

ANDA214091

FDA Approved

10/5/2021

TE Code

AB

On Market Since

10/5/2021

Pharmacological Classes

Amino Acids
Aromatic
Aromatic Amino Acid

Price Statistics

The NADAC for CARBIDOPA-LEVO ER 25-100 TAB has been published 198 times since Feb 8, 2023, and over the history we have for it it has declined 39.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1125 per EA
All-time high$0.1865 (Feb 15, 2023)
All-time low$0.1048 (Nov 20, 2024)
52-week high$0.1185
52-week low$0.1101
Median price$0.1384
Average price$0.1373
Largest weekly change-27.5% (Nov 20, 2024)
Weeks tracked198
Tracking sinceFeb 8, 2023

Price History

1W

+2.0%

1M

+2.2%

3M

-1.0%

6M

-2.7%

1Y

-5.8%

3Y

-25.8%

5Y

N/A

All

-39.7%

Generic Alternatives

The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 37% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CARBIDOPA-LEVO ER 25-100 TAB?

The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 25-100 TAB, manufactured by ScieGen Pharmaceuticals Inc., is $0.1125 per EA (NDC 50228046010), effective Nov 18, 2026.

How has the price of CARBIDOPA-LEVO ER 25-100 TAB changed over time?

Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 25-100 TAB has declined 39.7%. It has been tracked across 198 weekly CMS publications since Feb 8, 2023.

What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 25-100 TAB?

Since Feb 8, 2023, the NADAC for CARBIDOPA-LEVO ER 25-100 TAB has ranged from a low of $0.1048 (Nov 20, 2024) to a high of $0.1865 (Feb 15, 2023), with a median of $0.1384 per EA.

Are there cheaper alternatives to CARBIDOPA-LEVO ER 25-100 TAB?

Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVODOPA 25-100 TAB, is $0.0713 per EA — about 37% below CARBIDOPA-LEVO ER 25-100 TAB.

Who manufactures CARBIDOPA-LEVO ER 25-100 TAB?

CARBIDOPA-LEVO ER 25-100 TAB (NDC 50228046010) is labeled by ScieGen Pharmaceuticals Inc., and CMS classifies it as a generic product.